# Therapeutically leveraging metabolic vulnerabilities in breast cancer

> **NIH NIH R01** · MEDICAL COLLEGE OF WISCONSIN · 2024 · $176,918

## Abstract

Project Summary: Anti-cancer drug treatments often do not completely eradicate all cancer cells in the body,
leaving behind “drug-tolerant persister” cancer cells (DTPs) that can ultimately develop drug resistance to
cause tumor recurrence. The long-term goal of this line of investigation is to identify therapeutically targetable
vulnerabilities in DTPs to drive the development of treatment strategies for human malignancies. In estrogen
receptor alpha-positive (ER+) breast cancer, DTPs can persist for years despite endocrine therapies that
inhibit ER activity directly or via estrogen deprivation, causing tumor recurrences over a >20-year period. The
overall objective of this project is to determine how ER+ breast cancer cells utilize metabolic reprogramming to
tolerate and eventually overcome endocrine therapy. The central hypothesis is that ER+ breast cancer cells
survive endocrine therapy through a reversible metabolic switch that increases fatty acid metabolism,
mitochondrial respiration, and a protective oxidative stress response. The rationale for this project is that
definition of the metabolic vulnerabilities of DTPs in ER+ breast cancer will enable the rational development of
therapeutic strategies to suppress or eradicate DTPs and prevent cancer recurrence. The central hypothesis
will be tested by pursuing three specific aims: (1) Identify vulnerabilities in fatty acid metabolism and respiration
in DTPs surviving endocrine therapy in ER+ breast cancer; (2) Define the role of the oxidative stress response
in the persistence of DTPs in ER+ breast cancer; (3) Determine the degree of plasticity of metabolic
reprogramming in ER+ breast cancer during disease progression from endocrine tolerance to resistance. In the
first aim, endocrine therapy-induced changes in respiration and fatty acid metabolism will be measured in ER+
breast cancer cells grown in vitro and in vivo as orthotopic cell line- and patient-derived xenografts that yield
spontaneous metastases. Using pharmacological inhibitors of key metabolic signaling nodes, these studies will
determine contributions of fatty acid metabolism and respiration to DTP survival. The second aim will identify
the timing and contributions of oxidative stress and the oxidative stress response to breast cancer cell
persistence during endocrine therapy. In the third aim, we will analyze the role of metabolic adaptation in the
acquisition and maintenance of resistance to estrogen deprivation in human tumor tissues and preclinical
models. The research proposed in this application is innovative because it focuses on (a) identifying
vulnerabilities in DTPs to be exploited therapeutically, and (b) determining how adaptations in DTPs enable
drug resistance, which will drive the rational development of drugs to prevent and manage recurrence. The
proposed research is significant because it will provide strong scientific rationale for the development and
future clinical trials of treatment strategies leveraging m...

## Key facts

- **NIH application ID:** 11126975
- **Project number:** 3R01CA262232-04S1
- **Recipient organization:** MEDICAL COLLEGE OF WISCONSIN
- **Principal Investigator:** Todd W. Miller
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $176,918
- **Award type:** 3
- **Project period:** 2022-07-04 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11126975

## Citation

> US National Institutes of Health, RePORTER application 11126975, Therapeutically leveraging metabolic vulnerabilities in breast cancer (3R01CA262232-04S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11126975. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*